Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene

Annals of the Rheumatic Diseases

Volumn 64, Issue 7, 2005, Pages 1009-1014

  Rabinovich, E ^b   Livneh, A ^b   Langevitz, P ^b   Brezniak, N ^b   Shinar, E ^c   Pras, M ^b   Shinar, Y ^a,b  

^a HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MDA Central Blood Service   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEFV GENE; MORBIDITY; ONSET AGE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL ANALYSIS;

AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHRONIC DISEASE; CYTOSKELETAL PROTEINS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; HETEROZYGOTE; HUMANS; ISRAEL; JEWS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; SEVERITY OF ILLNESS INDEX;

EID: 21344474580     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.029447     Document Type: Article

References (50)

1. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.
2. Ollier W, Thomson W. Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am, 1992;18:741-59.
3. Moxley G, Cohen HJ. Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis. Rheum Dis Clin North Am 2002;28:39-58.
4. Jawaheer D, Seldin MF, Amos CI, Chen WW, Shigeta R, Etzel C, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003;48:906-16.
5. Fisher SA, Lanchbury JS, Lewis CM. Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16. Arthritis Rheum 2003;48:1200-6.
6. Eyre S, Barton A, Shephard N, Hinks A, Brintnell W, MacKay K, et al. Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole genome scan in a further series of 217 UK affected sibling pairs. Arthritis Rheum 2004;50:729-35.
7. Larsen A, Thoen J. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. Scand J Rheumatol 1987;16:395-401.
8. Orces CH, Del Rincon I, Abel MP, Escalante A. The number of deformed joints as a surrogate measure of damage in rheumatoid arthritis. Arthritis. Rheum 2002;47:67-72.
9. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA DRB1 genes on disease severity in rheuamatoid arthritis. Ann Intern Med 1992;117:801-6.
10. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. BMJ 1973;2:96-100.
11. Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-12.
12. Buchs N, di Giovani FS, Silverstri T, Vannier F, Duff GW, Miossec R. IL-1B and IL-1Ra polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001;2:222-8.
13. Morgan AW, Griffiths B, Ponchel F, Montague BM, Ali M, Gardner PP, et al. Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum 2000;46:556-9.
14. Rodrigeuz MR, Gonzalez-Escribano MF, Aguilar F, Velenzuela A, Garcia A, Nunez-Roldan A. Association of NRAMP1 promoter gene polymorphism with the susceptibility and radiological severity of rheumatoid arthritis. Tissue Antigens 2002;59:311-15.
15. Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 2000;20(suppl 26):S45-53.
16. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90:797-807.
17. French consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
18. Ozdogan H, Arisoy N, Kasapcapur O, Sever L, Caliskan S, Tuzuner N, et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997;24:323-7.
19. Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000;355:378-9.
20. Touitou I, Magne X, Molinari N, Navarro A, Quellec AL, Pico P, et al. MEFV mutations in Behçet's disease. Hum Mutation 2000;16:271-2.
21. Livneh A, Aksentijevich I, Langevitz P, Torosyan Y, G-Shoham N, Shinar Y, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behçet's disease (FMF-BD). Eur J Hum Genet 2001;9:191-6.
22. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr 2003;43:658-61.
23. Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, et al. Common mutations in the Mediterranean fever gene associate with rapid progression to disability in non-Ashekanazi Jewish multiple sclerosis patients. Genes Immun 2003;4:197-203.
24. Booth DR, Lachmann HJ, Gillmare JD, Booth SE, Hawkins PN. Prevalence and significance of the familial Mediterranean fever gene encoding pyrin Q148. QJM 2001;94:527-31.
25. Ozen S, Bakkaloglu A, Yilmaz E, Duzuva A, Balci B, Topaloglu R, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003;30:2014-18.
26. Heller H, Gafni J, Michaeli D, Shahin N, Sohar E, Erlich G, et al. The arthritis of familial Mediterranean fever. Arthritis Rheum 1966;9:1-17.
27. Dewalle M, Domingo C, Rozenbaum M, Ben-Chetrit E, Cattan D, Bernot A, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). Eur J Hum Genet 1998;6:95-7.
28. Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reiner P, et al. MEFV gene analysis in Armenian patients with familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet 1999;65:88-97.
29. Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Kozoil DE, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever patients. J Rheumatol 2000;27:1703-7.
30. Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 2001;44:1416-19.
31. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farell C, et al. The gene for familial Mediterranean fever is expressed in early leukocyte development and regulated in response to inflammatory mediators. Blood 2000;95:3223-31.
32. Matzner Y, Abedat S, Shapiro E, Eisenberg S, Bar-Gil-Shitrit A, Stepensky P, et al. Expression of the Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures. Blood 2000;96:727-31.
33. Stoffman N, Magal N, Shohat T, Lotan R, Koman S, Oron A, et al. Higher than expected carrier rate for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 2000;8:307-10.
34. Tsuchiya N, Ohashi J, Tokunaga K. Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev 2002;190:169-81.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001;102:272-6.
37. Pros E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosnen L, Dean M, et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. New Engl J Med 1992;326:1509-13.
38. Martinon F, Hofmann K, Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol 2001;11:R118-20.
39. Richards N, Schaner P, Diaz A, Stuckey J, Shelden E, Nadhwa A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001;276:39320-9.
40. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 2002;277:21119-22.
41. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003;11:591-604.
42. Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford), 2003;42(suppl 12):ii3-10.
43. Kory S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 2003;57:231-4.
44. Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet 1999;353:1415.
45. Manie S, Schmid-Alliana A, Kubar J, Ferrua B, Rossi B. Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-alpha. Involvement of protein kinase A stimulation. J Biol Chem 1993;268:13675-81.
46. Das SK, Mishra K, Ramakrishnan S, Srivastava R, Agarwal GG, Singh R, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2002;10:247-52.
47. Kanevskaia MZ, Chichasova NV, Varshavskii VA, Krel' AA. [The potentials of colchicine in the combined therapy of secondary amyloidosis in patients with rheumatoid arthritis.] Ter Arkh, 1991;63:93-7.
48. Abraham Z, Rozenbaum M, Rosner I. Colchicine therapy for low-dose-methotrexate-induced accelerated nodulosis in a rheumatoid arthritis patient. Dermatology 1999;26:691-4.
49. Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, Sharoni E, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz 2002;27:791-4.
50. Vandenbroeck K, Cunningham S, Goris A, Alloza I, Heggarty S, Graham C, et al. Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Artritis Rheum 2003;48:2773-8.